Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12-month price targets for Intra-Cellular Therapies' shares. Their ITCI share price forecasts range from $49.00 to $93.00. On average, they anticipate the company's share price to reach $69.29 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has decreased by 7.8% and is now trading at $48.77.
View the best growth stocks for 2023 here.

Intra-Cellular Therapies saw a decline in short interest in January. As of January 15th, there was short interest totaling 2,590,000 shares, a decline of 19.3% from the December 31st total of 3,210,000 shares. Based on an average daily volume of 627,400 shares, the short-interest ratio is currently 4.1 days.
View Intra-Cellular Therapies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ITCI earnings forecast.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.29. The biopharmaceutical company had revenue of $71.87 million for the quarter, compared to analysts' expectations of $64.95 million. Intra-Cellular Therapies had a negative net margin of 158.39% and a negative trailing twelve-month return on equity of 45.52%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.21%), Assenagon Asset Management S.A. (0.08%), Strs Ohio (0.02%), Quantum Private Wealth LLC (0.02%), Hennion & Walsh Asset Management Inc. (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITCI stock can currently be purchased for approximately $48.77.

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $4.62 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284,130,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

The company employs 512 workers across the globe.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.